Karyopharm Therapeutics (KPTI) Non-Current Assets (2012 - 2025)

Karyopharm Therapeutics has reported Non-Current Assets for 14 years, with the latest figure at $5.3 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Assets fell 33.76% year-over-year to $5.3 million; the trailing twelve-month figure through Dec 2025 stood at $26.2 million (up 8.39% YoY), and the FY2025 full-year result was $5.3 million, down 33.76% from the prior year.
• Non-Current Assets for Q4 2025 stood at $5.3 million, down from $6.5 million in the prior quarter.
• The five-year high for Non-Current Assets was $29.7 million in Q4 2021, with the low at $4.7 million in Q3 2024.
• Historically, Non-Current Assets has averaged $10.0 million across 5 years, with a median of $7.4 million in 2023.
• Annual changes were most pronounced in 2021 — Non-Current Assets tumbled 78.99% — and 2025, when it surged 37.39%.
• Karyopharm Therapeutics' Non-Current Assets stood at $29.7 million in 2021, then sank by 73.03% to $8.0 million in 2022, then declined by 18.64% to $6.5 million in 2023, then increased by 22.08% to $8.0 million in 2024, then sank by 33.76% to $5.3 million in 2025.
• The last three Non-Current Assets figures came in at $5.3 million (Q4 2025), $6.5 million (Q3 2025), and $7.0 million (Q2 2025), per Business Quant data.